Protara Therapeutics Inc
NASDAQ:TARA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Protara Therapeutics Inc
Free Cash Flow
Protara Therapeutics Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Protara Therapeutics Inc
NASDAQ:TARA
|
Free Cash Flow
-$56.5m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-12%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Free Cash Flow
$17.8B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
1%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Free Cash Flow
$9.5B
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Free Cash Flow
$8.1B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Free Cash Flow
$3.2B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Free Cash Flow
$3.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
13%
|
CAGR 10-Years
19%
|
|
Protara Therapeutics Inc
Glance View
Protara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. The company is headquartered in New York City, New York and currently employs 31 full-time employees. The company went IPO on 2014-10-22. The firm is focused on identifying therapies for the treatment of cancer and rare diseases. The firm's pipeline includes TARA-002 and IV Choline Chloride. The firm's lead product pipeline is TARA 002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is an investigational, intravenous (IV) phospholipid substrate replacement therapy, which is in development for patients receiving parenteral nutrition (PN) who have intestinal failure-associated liver disease (IFALD).
See Also
What is Protara Therapeutics Inc's Free Cash Flow?
Free Cash Flow
-56.5m
USD
Based on the financial report for Dec 31, 2025, Protara Therapeutics Inc's Free Cash Flow amounts to -56.5m USD.
What is Protara Therapeutics Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-12%
Over the last year, the Free Cash Flow growth was -57%. The average annual Free Cash Flow growth rates for Protara Therapeutics Inc have been -29% over the past three years , -18% over the past five years , and -12% over the past ten years .
